Harel Insurance Investments & Financial Services Ltd. Sells 2,828 Shares of Cencora, Inc. $COR

Harel Insurance Investments & Financial Services Ltd. decreased its position in shares of Cencora, Inc. (NYSE:COR) by 11.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,640 shares of the company’s stock after selling 2,828 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Cencora were worth $6,798,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in COR. United Bank raised its holdings in Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after buying an additional 305 shares during the last quarter. Nebula Research & Development LLC bought a new stake in shares of Cencora during the second quarter valued at about $595,000. Treasurer of the State of North Carolina raised its stake in Cencora by 7.9% in the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock valued at $25,647,000 after purchasing an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC grew its position in Cencora by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock valued at $747,000 after acquiring an additional 1,253 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of Cencora by 26.0% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock worth $22,025,000 after buying an additional 15,154 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on COR shares. UBS Group boosted their target price on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wells Fargo & Company dropped their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Citigroup lowered their price target on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. William Blair assumed coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Finally, Weiss Ratings lowered Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $367.75.

Insiders Place Their Bets

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the purchase, the director directly owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.38% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

NYSE COR opened at $296.71 on Thursday. The stock has a market capitalization of $57.73 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 1.68 and a beta of 0.58. The stock has a 50-day moving average of $277.99 and a 200 day moving average of $317.98. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.Cencora’s revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Cencora announced that its Board of Directors has authorized a share buyback plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.